MedTrace Logo

Lithium Versus Quetiapine in Treatment Resistant Depression

NCT03004521 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2021-03-05

No results posted yet for this study

Summary

LQD is a multicentre randomised clinical trial comparing the clinical and cost effectiveness of lithium versus quetiapine when used as add-on therapies to antidepressant medication for patients with treatment resistant depression. The Lithium versus Quetiapine in Depression (LQD) study will assess patients over 12 months to establish which (if any) treatment is more likely to improve TRD over a long duration of time. Professor Anthony Cleare is the Chief Investigator and recruitment began in November 2016.

Conditions

  • Depressive Disorder, Treatment-Resistant

Interventions

DRUG

Quetiapine

Quetipatine prescribed in addition to the patient's existing antidepressant treatment.

DRUG

Lithium

Lithium prescribed in addition to the patient's existing antidepressant treatment.

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Newcastle University

    collaborator OTHER

  • Oxford Health NHS Foundation Trust

    collaborator OTHER_GOV

  • Northumberland, Tyne and Wear NHS Foundation Trust

    collaborator OTHER

  • South London and Maudsley NHS Foundation Trust

    collaborator OTHER

  • Tees, Esk and Wear Valleys NHS Foundation Trust

    collaborator UNKNOWN

  • Sussex Partnership NHS Foundation Trust

    collaborator OTHER

  • Avon and Wiltshire Mental Health Partnership NHS Trust

    collaborator OTHER_GOV

  • King's College London

    lead OTHER

Principal Investigators

  • Anothony Cleare · Professor of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-04-30
Completion
2021-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004521 on ClinicalTrials.gov